Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Biotechnology

Healthcare
$42.53 -1.86%

-$0.62 today

Market cap
$800.84M
Beta
1.18
P/E (TTM)
1.7
EPS (TTM)
$19.78
52W Low $18.14High $52.24

Volume 0.24M

Average 0.36M

RIGL Sales of Investments

Cash received from selling or redeeming investments.

Rigel Pharmaceuticals, Inc.NASDAQ: RIGL

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments grows, but more slowly than its trailing trend

Q1 FY2026 sales of investments of $15.95M rose 43.6% year over year, behind the +55.1% change in trailing-twelve-month sales of investments. Sequentially, it rose 17.7% from the prior quarter. Over 3 fiscal years it compounded at -15.5% a year.

Context

  • Sales of investments amounted to 20.8% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +43.6% toward the trailing-twelve-month pace of +55.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.95M+17.7% QoQ
Last fiscal yearDec 2025
$61.13M+54.0% YoY
LTMMar 2026
$65.97M+55.1% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+43.6%——
1 year+54.0%——
3-year CAGR-15.5%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
61.13M USD
Year-over-year change
+54.0%
4-year CAGR
-0.4%

Sales of Investments vs competitors

How RIGL compares with its peers on the latest reported figures

  • RIGL's LTM Mar 2026 sales of investments of $65.97M is the 7th largest of the 10 companies compared; the peer median is $110.41M.
  • Its year-over-year change of +55.1% is the highest of 8, against a peer median of -19.9%.
  • Sales of investments amounts to 22.0% of revenue for RIGL, versus a peer median of 33.1%.
RIGL Competitors Peer median
Sales of Investments for RIGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EXELExelixis, Inc.LTM Jul 2026$805.24M -19.9%-1.3%33.1%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$614.95M +3.0%+30.4%87.6%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$306.48M -49.2%+5.7%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$221.34M -5.3%-8.2%634.9%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$110.41M -38.6%-2.0%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$67.84M +28.1%-17.5%12922.7%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$65.97M +55.1%-15.5%22.0%
VSTMVerastem, Inc.LTM Mar 2026$119K -100.4%-93.0%0.2%
ANLAdlai Nortye Ltd.LTM Jun 2024$0 —-61.4%0.0%
MREOMereo BioPharma Group plcLTM Mar 2026$0 ——0.0%
Peer median (excluding RIGL) $110.41M-19.9%-5.1%33.1%

Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.91M)(58.57M)(25.09M)17.49M367.02M
Depreciation & Amortization1.16M998K1.24M2.23M2.42M
Deferred Income Tax0000(245.85M)
Stock-Based Compensation9.49M12.39M8.81M12.39M12.71M
Change in Working Capital9.72M(29.05M)9.52M153K(19.51M)
Accounts Receivables501K(24.85M)9.77M(11.07M)(10.15M)
Inventory(4.88M)(2.38M)1.17M764K(5.64M)
Accounts Payables41K3.79M(366K)(3.8M)3.85M
Other Working Capital14.05M(5.61M)(1.06M)14.26M(7.58M)
Other Non-Cash Items3.43M481K(213K)(788K)(41.13M)
Operating Cash Flow5.88M(73.76M)(5.74M)31.47M75.66M
Capital Expenditures(627K)(450K)(15M)(396K)0
Acquisitions (Net)00000
Purchases of Investments(141.46M)(28.89M)(31.21M)(35.27M)(153.49M)
Sales of Investments62.05M101.23M41.65M39.7M61.13M
Other Investing Activities0893K259K98K0
Investing Cash Flow(80.04M)72.78M(4.3M)4.13M(92.37M)
Debt Repayment019.54M19.95M0(7.5M)
Common Stock Issued00008.1M
Common Stock Repurchased000(10M)0
Dividends Paid00000
Other Financing Activities62.68M(12.99M)(1.58M)(1.64M)0
Financing Cash Flow62.68M6.55M18.37M(11.64M)601K
Effect of Forex Changes00000
Net Change in Cash(11.48M)5.57M8.33M23.96M(16.11M)
Free Cash Flow5.25M(74.21M)(20.74M)31.08M75.66M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Intrinsic Alpha fair value

Locked

Current Price

$42.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.